- Home
- BDSX vs FULC Comparison
BDSX vs FULC Comparison
Compare BDSX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDSX
- FULC
- Stock Information
- Founded
- BDSX 2005
- FULC 2015
- Country
- BDSX United States
- FULC United States
- Employees
- BDSX N/A
- FULC N/A
- Industry
- BDSX Precision Instruments
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- BDSX Health Care
- FULC Health Care
- Exchange
- BDSX Nasdaq
- FULC Nasdaq
- Market Cap
- BDSX 200.0M
- FULC 221.5M
- IPO Year
- BDSX 2020
- FULC 2019
- Fundamental
- Price
- BDSX $1.20
- FULC $2.97
- Analyst Decision
- BDSX Strong Buy
- FULC Hold
- Analyst Count
- BDSX 4
- FULC 10
- Target Price
- BDSX $3.08
- FULC $7.44
- AVG Volume (30 Days)
- BDSX 732.5K
- FULC 816.2K
- Earning Date
- BDSX 11-01-2024
- FULC 11-13-2024
- Dividend Yield
- BDSX N/A
- FULC N/A
- EPS Growth
- BDSX N/A
- FULC N/A
- EPS
- BDSX N/A
- FULC N/A
- Revenue
- BDSX $65,562,000.00
- FULC $80,871,000.00
- Revenue This Year
- BDSX $46.97
- FULC $2,821.96
- Revenue Next Year
- BDSX $30.43
- FULC N/A
- P/E Ratio
- BDSX N/A
- FULC N/A
- Revenue Growth
- BDSX 48.92
- FULC 2987.86
- 52 Week Low
- BDSX $1.11
- FULC $2.86
- 52 Week High
- BDSX $2.21
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- BDSX 28.77
- FULC 32.31
- Support Level
- BDSX $1.11
- FULC $2.86
- Resistance Level
- BDSX $1.45
- FULC $3.94
- Average True Range (ATR)
- BDSX 0.09
- FULC 0.22
- MACD
- BDSX -0.02
- FULC -0.00
- Stochastic Oscillator
- BDSX 24.32
- FULC 10.19
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.